296 related articles for article (PubMed ID: 22369444)
41. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
You JHS; Cho WCS; Ming WK; Li YC; Kwan CK; Au KH; Au JS
PLoS One; 2021; 16(3):e0247860. PubMed ID: 33647045
[TBL] [Abstract][Full Text] [Related]
42. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.
de Marinis F; Grossi F
Oncologist; 2008; 13 Suppl 1():14-20. PubMed ID: 18263770
[TBL] [Abstract][Full Text] [Related]
43. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.
Simon GR; Extermann M; Chiappori A; Williams CC; Begum M; Kapoor R; Haura EB; Ismail-Khan R; Schell MJ; Antonia SJ; Bepler G
Cancer; 2008 May; 112(9):2021-9. PubMed ID: 18300255
[TBL] [Abstract][Full Text] [Related]
44. Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer.
Wang H; Zeng C; Li X; Wang Y; Li X; Ge W
Future Oncol; 2019 Jan; 15(2):181-191. PubMed ID: 30320506
[TBL] [Abstract][Full Text] [Related]
45. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
46. Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions.
Custodio A; de Castro J
Crit Rev Oncol Hematol; 2012 Jun; 82(3):338-60. PubMed ID: 21908201
[TBL] [Abstract][Full Text] [Related]
47. Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2.
Schluckebier L; Garay OU; Zukin M; Ferreira CG
Lung Cancer; 2015 Sep; 89(3):274-9. PubMed ID: 26143106
[TBL] [Abstract][Full Text] [Related]
48. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.
Lyseng-Williamson KA
Pharmacoeconomics; 2010; 28(1):75-92. PubMed ID: 20014878
[TBL] [Abstract][Full Text] [Related]
49. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.
Nadler E; Forsyth M; Satram-Hoang S; Reyes C
J Thorac Oncol; 2012 Jan; 7(1):212-8. PubMed ID: 22124474
[TBL] [Abstract][Full Text] [Related]
50. Gefitinib in the treatment of advanced non-small-cell lung cancer.
Reck M
Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
[TBL] [Abstract][Full Text] [Related]
51. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
[TBL] [Abstract][Full Text] [Related]
52. Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.
Zhu J; Li T; Wang X; Ye M; Cai J; Xu Y; Wu B
BMC Cancer; 2013 Jan; 13():39. PubMed ID: 23360224
[TBL] [Abstract][Full Text] [Related]
53. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Manegold C; Gatzemeier U; Buchholz E; Smith RP; Fandi A
Clin Lung Cancer; 2005 May; 6(6):343-9. PubMed ID: 15943894
[TBL] [Abstract][Full Text] [Related]
54. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.
Horgan AM; Bradbury PA; Amir E; Ng R; Douillard JY; Kim ES; Shepherd FA; Leighl NB
Ann Oncol; 2011 Aug; 22(8):1805-11. PubMed ID: 21273345
[TBL] [Abstract][Full Text] [Related]
55. Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature.
Tassinari D; Carloni F; Santelmo C; Tamburini E; Lazzari Agli L; Tombesi P; Sartori S
Rev Recent Clin Trials; 2009 Jan; 4(1):27-33. PubMed ID: 19149760
[TBL] [Abstract][Full Text] [Related]
56. [Second-line treatment for advanced non-small-cell lung cancers].
Akita H
Gan To Kagaku Ryoho; 2005 Jan; 32(1):15-8. PubMed ID: 15675575
[TBL] [Abstract][Full Text] [Related]
57. Considerations for second-line therapy of non-small cell lung cancer.
Stinchcombe TE; Socinski MA
Oncologist; 2008; 13 Suppl 1():28-36. PubMed ID: 18263772
[TBL] [Abstract][Full Text] [Related]
58. Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).
Chouaid C; Le Caer H; Corre R; Crequit J; Locher C; Falchero L; Dujon C; Berard H; Monnet I; Vergnenegre A
Clin Lung Cancer; 2013 Mar; 14(2):103-7. PubMed ID: 22682669
[TBL] [Abstract][Full Text] [Related]
59. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
60. A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis.
Nelson RE; Stenehjem D; Akerley W
Lung Cancer; 2013 Dec; 82(3):461-8. PubMed ID: 24074609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
